-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Immunic, Lowers Price Target to $5

Benzinga·03/02/2026 11:36:37
Listen to the news
HC Wainwright & Co. analyst Matthew Caufield maintains Immunic (NASDAQ:IMUX) with a Buy and lowers the price target from $8 to $5.